NORTHBROOK, Ill., April 17, 2025 /PRNewswire/ -- Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose administration for the first ...

Following promising phase 1 data, TCMCB07 is being further evaluated in a phase 2 trial for the treatment of patients with ...

The first patient has received TCMCB07 in a phase 2 trial to prevent weight loss in patients with metastatic colorectal ...